文献速递妇科产科

宫颈癌幸存者中原发性肛门癌与口咽癌的风险

Second primary anal and oropharyngeal cancers in cervical cancer survivors.
PubMed 文献 · Am J Obstet Gynecol · 2019-05-22

基于监测、流行病学和最终结果计划-9数据,纳入1973年至2014年确诊的21060例宫颈鳞状细胞癌女性,计算肛门癌和口咽癌的标准化发病比。幸存者口咽癌标准化发病比为4.36(95%CI 1.19-11.15),肛门癌为2.20(95%CI 1.28-3.52),诊断后10年及以上风险仍显著升高。

要点

  • 宫颈鳞癌幸存者口咽癌风险升高(标准化发病比4.36,95%CI 1.19-11.15)。
  • 宫颈鳞癌幸存者肛门癌风险升高(标准化发病比2.20,95%CI 1.28-3.52)。
  • 诊断后120个月及以上,口咽癌和肛门癌风险均仍升高。

核心结论

  • 宫颈鳞状细胞癌幸存者肛门癌和口咽癌风险显著升高,诊断后10年及以上风险仍显著。
  • 医疗保健提供者和幸存者应知晓这一风险升高。
  • 亟待开发有效且经济的肛门癌和口咽癌监测方法。

研究设计与样本

  • 基于监测、流行病学和最终结果计划-9数据的基于人群的队列研究。
  • 纳入1973年至2014年确诊的21060例宫颈鳞状细胞癌女性。
  • 计算肛门癌和口咽癌的标准化发病比,并按年龄(20-53岁、54岁及以上)和潜伏期(2-11、12-59、60-119、120个月及以上)分层。

主要发现

  • 口咽癌标准化发病比为4.36(95%CI 1.19-11.15)。
  • 肛门癌标准化发病比为2.20(95%CI 1.28-3.52)。
  • 20-53岁确诊宫颈癌者肛门癌风险升高(标准化发病比3.53,95%CI 1.15-8.23)。
  • 54岁及以上确诊宫颈癌者仅口咽癌风险升高(标准化发病比5.04,95%CI 1.37-12.91)。
  • 诊断后120个月及以上,口咽癌标准化发病比为7.97(95%CI 2.17-20.42),肛门癌为2.60(95%CI 1.34-4.54)。

关键数值与推荐

  • 口咽癌需筛查人数为282。
  • 肛门癌需筛查人数为1272。
  • 口咽癌和肛门癌需筛查人数均显著低于宫颈癌需筛查人数。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human papilloma virus infection is responsible for approximately 31,500 new cancers in the United States annually. Almost all cervical cancers are linked to human papilloma virus infection. As early identification and treatment of cervical cancer improve, the incidence of cervical cancer has decreased and survival has improved. However, survivors continue to remain at risk for other human papilloma virus-related malignancies. The purpose of this study was to assess the risk of primary anal and oropharyngeal cancers among women with a history of squamous cell carcinoma of the cervix. STUDY DESIGN: A population-based cohort of 21,060 women diagnosed with cervical squamous cell carcinoma from 1973 through 2014 was identified from the Surveillance, Epidemiology, and End Results Program-9 data. Standardized incidence ratios for anal and oropharyngeal cancers were calculated to estimate the risk of a second primary human papilloma virus-related malignancy based on incidence in the general population. Results were further stratified by age (20-53, 54 years old or older) and latency period (2-11, 12-59, 60-119, 120 months or longer). The number needed to screen for oropharyngeal and anal cancers was estimated using study results and Centers for Disease Control and Prevention-reported incidence rates. RESULTS: Cervical squamous cell cancer survivors had a higher risk of being diagnosed with oropharyngeal cancer (standardized incidence ratio, 4.36, 95% confidence interval, 1.19-11.15) and anal cancer (standardized incidence ratio, 2.20, 95% confidence interval, 1.28-3.52). Patients diagnosed with cervical cancer between ages 20 and 53 years had an increased risk of anal cancer (standardized incidence ratio, 3.53, 95% confidence interval, 1.15-8.23). Age 54 years or older at cervical cancer diagnosis was associated with increased oropharyngeal cancer risk only (standardized incidence ratio, 5.04, 95% confidence interval, 1.37-12.91). Latency stratification was significant for increased OPC risk between 2-11 months and 12-59 months after diagnosis. At 120 months or longer, there was an increased risk of both oropharyngeal cancer (standardized incidence ratio, 7.97, 95% confidence interval, 2.17-20.42) and anal cancer (standardized incidence ratio, 2.60, 95% confidence interval, 1.34-4.54). The estimated number needed to screen for oropharyngeal cancer (number needed to screen for oropharyngeal cancer, 282) and anal cancer (number needed to screen for anal cancer, 1272) is significantly less than the number needed to screen for cervical cancer. CONCLUSION: Squamous cell cervical cancer survivors have a substantially increased risk of anal and oropharyngeal cancers. This increased risk is significant 10 or more years after the cervical cancer diagnosis. Health care providers and survivors should be aware of this increased risk. The development of effective and economical surveillance methods for anal and oropharyngeal cancers in cervical cancer survivors is urgently needed.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Papatla K, Halpern MT, Hernandez E, et al. Second primary anal and oropharyngeal cancers in cervical cancer survivors. Am J Obstet Gynecol. 2019. PMID: 31128108. doi:10.1016/j.ajog.2019.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。